Narrative Drift in Biopharma During Quiet Periods
Michael Etheredge is VP of Product Development at QuestionFuel, where he leads how the firm measures and corrects the way AI answer engines describe companies. He was featured by the Southern Economic Development Council on how AI is changing the way companies research communities and regions.
Biopharma companies often go through periods where there is not much new to say publicly. A clinical program is advancing, data is pending, and investor materials are in place. The company may be preparing for a future milestone while the market has limited new information to evaluate.
To leadership, that feels like a quiet period. To AI systems, it creates a narrative problem, because the absence of new information from the company does not create an absence of information overall.
Key takeaways
- During quiet periods, AI answers keep forming from whatever public material already exists, which is usually older material.
- Drift in biopharma is more often an interpretation problem than a visibility problem: the company is named but the science, stage, or category is wrong.
- Outdated framing gains authority when nothing newer is available to balance it.
- Quiet periods are the best window to detect and correct drift, because there is time to strengthen sources before the milestone.
- The fix is clearer public source material, not manipulation of the answer.
Quick answer: Narrative drift during a quiet period happens when a biopharma company has little new public information to offer, so AI systems continue explaining the company through older press releases, legacy descriptions, and third-party summaries that no longer reflect its current stage or strategy. The company usually still appears in the answer. What drifts is the interpretation: the mechanism, the development stage, the comparison set, or the significance of recent progress.
When there is little new public information, AI tools rely on older sources, outdated summaries, incomplete descriptions, and third-party interpretations that no longer reflect the company's current position. That is how narrative drift begins.
Why does the AI narrative lag behind the company?
In biopharma, timing matters. A company may be approaching an important readout, advancing a trial, refining the target patient population, strengthening the scientific rationale, or preparing the market for a more specific interpretation of the asset.
If the public information available to AI systems is older, thin, fragmented, or hard to interpret, AI continues to explain the company through an outdated lens. That creates a gap between what the company understands internally, what public materials are meant to communicate, what investors and stakeholders need to know, and what AI tools are actually saying. The gap matters long before a formal announcement is made.
How do quiet periods amplify old information?
AI systems answer from the information they can access, understand, and synthesize. If the newest company narrative is not clearly expressed across public sources, older information carries more weight than it should.
That older material includes prior press releases, legacy company descriptions, outdated pipeline summaries, early-stage scientific explanations, old investor commentary, third-party profiles, clinical trial listings without enough context, and news coverage from a previous financing or strategic phase. None of those sources is necessarily wrong on its own. The problem is that together they no longer tell the full story, and during a quiet period the lack of newer context makes older context feel more authoritative than it is.
Is the real risk visibility or interpretation?
Many teams treat AI visibility as a search problem: do we show up? In biopharma the larger issue is usually interpretation. AI may name the company and still miss what matters most.
It can describe the mechanism too broadly, understate the market opportunity, fail to connect a program to the right clinical context, compare the asset to the wrong category, omit recent trial progress, frame the company through an older stage of development, or treat a differentiated approach as a generic one. That is narrative drift. The company is present, but the story is not aligned.
Why does this matter for investor relations?
Investor relations teams work to reduce confusion, helping the market understand strategy, milestones, risk profile, and value drivers. When investors, analysts, journalists, or potential partners use AI tools as part of early research, they may encounter an interpretation that does not reflect the company's current narrative.
That shapes the questions they ask and the assumptions they bring into a conversation. It affects how they compare the company to others in the space. In some cases it reinforces outdated information at the exact moment the company needs the market to understand a newer story. A source alignment review is the practical way to find that exposure before it reaches a call.
What should biopharma teams review during a quiet period?
During quiet periods, companies should understand how AI systems answer the questions that matter most: what the company is developing, what the lead asset is, what the mechanism of action is, what stage the program is in, what data or milestone is expected next, what makes the approach differentiated, what the biggest risks are, who the relevant competitors are, and what investors should know.
The goal is not to manipulate the answer. The goal is to determine whether the answer is accurate, current, complete, and aligned with the public narrative the company has already made available.
When is the best time to detect drift?
Narrative drift is easier to address before the market moment arrives. A company that waits until after a major announcement has less room to correct outdated assumptions quickly.
That is what makes quiet periods useful. They create an opportunity to review the public narrative, identify where AI answers are misaligned, and strengthen the source material AI systems will rely on later. That work includes website pages, pipeline descriptions, FAQs, investor content, disease-state explainers, source consistency, and plain-language summaries that make the company's story easier to interpret.
Frequently asked questions
What is narrative drift in biopharma?
Narrative drift in biopharma is the divergence between a company's current scientific and strategic position and the way AI systems describe it, caused by AI synthesizing older or third-party sources that have not caught up to the company's present stage.
Why are quiet periods especially risky for AI narrative accuracy?
Because AI answers keep being generated whether or not the company is publishing. With no new authoritative material to weigh, older coverage, speculation, and legacy descriptions carry more influence than they otherwise would.
Does staying quiet mean a company is invisible to AI?
No. A quiet period pauses the company's own communication, not the formation of AI answers. Stakeholders keep researching, competitors keep publishing, and older content keeps influencing interpretation.
Can a company address drift without making a new disclosure?
Often yes. Much of the fix is clarity rather than new information: consistent company descriptions, plain-language mechanism explanations, accurate stage language, dated context on legacy pages, and internal linking between related material.
What kinds of drift show up most often in biopharma answers?
The most common are an overly broad mechanism description, an outdated development stage, the wrong comparison set, missing recent trial progress, and a differentiated approach described in generic terms.
How do you know whether the AI narrative is improving?
Re-run the same stakeholder questions on a set cadence and compare answers over time. Improvement looks like current stage language, newer milestones appearing, and comparisons landing in the correct category.
Quiet does not mean invisible
A quiet period does not mean the company's narrative stops moving. AI systems keep forming answers, stakeholders keep researching, competitors keep publishing, and older content keeps influencing interpretation. The question is whether the current public narrative is strong enough to guide the answer.
For biopharma companies approaching important milestones, narrative drift is not only a communications issue. It is a market understanding issue.
Related: read our main article on AI narrative drift and the DRIFT detection walkthrough for the step-by-step review process.